^
Association details:
| Biomarker: | SETD2 deletion |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer
Published date:
09/11/2023
Excerpt:
We tested the effects of the DNA HMA 5-aza-2'-dexoxydytidine (DAC), the PARPi talazoparib (BMN-673), and both in combination in human ccRCC models with or without SETD2 deficiency….Finally, the combination effectively suppressed the growth of SETD2-deficient ccRCC in in vivo mouse models.
DOI:
https://doi.org/10.1158/0008-5472.CAN-23-0401
